MoneywebNOW took a look at whether GLP-1 drugs present a good investment opportunity, future inflation expectations and more.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden administration’s drug-price cuts.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

FCPI's portfolio shows resilience in consumer staples and healthcare, but faces uncertainty in energy and basic materials ...

The RBI was expected to start an interest rate cut cycle in the second half of 2024 as it had projected inflation to average 4% — its median target — through July-September. Yes, the National ...

We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...